賽沃替尼為MET異常患者帶來全新希望。
MET14號外顯子跳躍突變,賽沃替尼成為治療新標準
浙江大學博士生導師,教授
浙江大學醫學院附屬第一醫院呼吸危重癥醫學科主任
肺部疾病診療中心主任
全國首批呼吸專科醫師培訓基地主任
中華醫學會呼吸病分會全國常委
中華醫學會呼吸病分會肺癌學組副組長
中國醫促會胸部腫瘤分會副主委
浙江省醫師協會呼吸醫師分會會長
浙江省醫學會呼吸病分會前任主任委員
浙江省抗癌協會肺癌專業組副主任委員
[1] 非小細胞肺癌分子病理檢測臨床實踐指南(2021版)[J].中華病理學雜志,2021, 50(4):323-332.
[2] NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer. Version 1. 2022.
[3] 中國臨床腫瘤學會(CSCO)非小細胞肺癌診療指南2021版.
[4] Mark Award,Jessica Lee, Russell Madison, et al.2020 ASCO. Abstract 9511.
[5] Sequist L V, Han J Y, Ahn M J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. The Lancet Oncology, 2020, 21(3): 373-386.
[6] Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer[J]. Expert Opin Investig Drugs. 2018;27(4):363-375.[2]Bean J, Brennan C, Shih JY, et al.
[7] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proc Natl Acad Sci U S A. 2007;104(52):20932-7.
[8] Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. 2018 ESMO Congress. Abstract LBA50.
[9] Wang Y, Li L, Han R, et al. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib[J]. Lung Cancer. 2018;118:105-110.
[10] K.Haratani, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532-1539.
加硒教授微信:623296388,送食療電子書,任選一本